GT Biopharma, Inc. - Common Stock (GTBP)

CUSIP: 36254L308

Q1 2025 13F Holders as of 31 Mar 2025

Type / Class
Equity / Common Stock
Shares outstanding
3,148,458
Total 13F shares
99,688
Share change
-1,145,192
Total reported value
$220,497
Price per share
$2.15
Number of holders
20
Value change
-$29,000,935
Number of buys
5
Number of sells
6

Quarterly Holders Quick Answers

What is CUSIP 36254L308?
CUSIP 36254L308 identifies GTBP - GT Biopharma, Inc. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of GT Biopharma, Inc. - Common Stock (GTBP) as of Q1 2025

As of 31 Mar 2025, GT Biopharma, Inc. - Common Stock (GTBP) was held by 20 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 99,688 shares. The largest 10 holders included GEODE CAPITAL MANAGEMENT, LLC, CITADEL ADVISORS LLC, BANK OF MONTREAL /CAN/, VANGUARD GROUP INC, WELLS FARGO & COMPANY/MN, BlackRock, Inc., MORGAN STANLEY, OSAIC HOLDINGS, INC., UBS Group AG, and Newbridge Financial Services Group, Inc.. This page lists 20 institutional shareholders reporting positions in this security for the Q1 2025 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.